Tagged with EY

Pharma The general manager of Drogsan, Ersan Kuçuk elaborates on the company’s efforts in shifting towards more value-added pharmaceutical products, specifically within the realm of biosimilars, while highlighting his ambitions in expanding the company’s presence within OTC. He also illustrates the decision to move Drogsan’s R&D department to the Gazi University…

pharma Consumer healthcare products manufacturer Winalite is working to penetrate the Turkish market, but with regulations complicating bringing their portfolio from China, general manager Arafat Yadigar is looking to develop a Turkey specific portfolio in collaboration with the Turkish health products and pharmaceutical manufacturing sectors.  Your promotion to General Manager is…

pharma Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s future in Turkey. As an introduction for our readers, Ozgur, can you please give an overview of where J&J Turkey…

pharma Nil Tunaşar, managing partner of Transorient, discusses significance of tracking performance metrics among 3PL providers, the organization’s technology overhaul, and also highlights the type of logistics solutions encompassed under Transorient’s Life Sciences and Biopharma line of business. As an introduction for our readers, Nil, please provide some insight into Transorient’s…

pharma Matthias Diewald (MD) and Asli Volkan (AV) elaborate on HELM Kimya’s longstanding presence within Turkey and the type of market opportunities available for co-development and contract manufacturing. They also explain the significance of establishing strong partnerships with local industry leaders and how this can effectively drive future success for the company’s…

pharma The general manager of Ali Raif, Muzaffer Bal illustrates the various success factors that allowed the company to secure market leading positions within Turkey and across Europe, while also highlighting how the company has adapted its portfolio to shifting market dynamics. Muzaffer, as an introduction for our readers, please provide…

pharma Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market as a Turkish brand. As an introduction Haluk, can you tell us what your initial aspirations were in starting Matriks…

pharma Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the pharmaceutical industry. To begin, Dr. Özgören, could you give us an overview of the intent behind the BioIzmir project? The…

Turkey BMS Turkey’s new general manager discusses Opdivo (nivolumab) their revolutionary new product for squamous non-small cell lung cancer, their registry of 1200 patients in Turkey with melanoma, potential developments in pharmaceutical pricing through alternative reimbursement models, and BMS’ role in helping to shape health policy around oncology given their revolutionary immuno-oncology…

Pharma Miroslav Secerov, VP Sales & Marketing NATEC, explains the choice of Mauritius for NATEC’s headquarters as well as the unique assets that make Mauritius the ideal business location. He also analyses Mauritius’ recent emphasis on development of the life sciences sector and the public-private relationship required to make that a…

Pharma Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a real public health policy is another way of combatting the increase in health spending, and how France needs to reach…

Pharma Michel Dutree, former director general of the Dutch association for pharmaceutical innovators, gives a detailed overview of the changes happening in the Dutch pharmaceutical industry, and the Netherlands’ role at the European level as the “laboratory of Europe.” It’s been four years since your last interview with PBR; what do…